Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

POINT Biopharma Global Inc. - Common Stock (NQ: PNT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 12.49 (70)
Ask (Size) 12.51 (49)
Prev. Close 12.50
Today's Range N/A - N/A
52wk Range 12.45 - 12.51
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole... 
Via Benzinga
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c 
Via Benzinga

Performance

More News

Read More
Why is Prostate Cancer Focused Lantheus Stock Trading Lower Today?
Via Benzinga
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Exposures Death
Recap: POINT Biopharma Global Q3 Earnings
Via Benzinga
Top 5 Health Care Stocks That May Collapse In November
Via Benzinga
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Via PressReach
POINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT Biopharma Global, Inc. - PNT
From Kahn Swick & Foti, LLC
Via Business Wire
Stock Market Ends On High Note Even As Yields Soar; Tesla In Focus: Weekly Review
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Why Point BioPharma Global Stock Skyrocketed 86% This Week
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2023
Via Benzinga
Why Eli Lilly Stock Was Looking Sickly Today
Via The Motley Fool
Crude Oil Moves Higher; POINT Biopharma Global Shares Jump
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Shares of Point Biopharma Global Are Soaring Tuesday
Via The Motley Fool
Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Down Over 200 Points; US Job Openings Rise In August
Via Benzinga
Topics Stocks
Exposures US Equities
Point Biopharma Stock Nearly Doubles On Eli Lilly Deal
Via Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Vericity, Inc. (Nasdaq - VERY), POINT Biopharma Global, Inc. (Nasdaq - PNT), Blue Apron Holdings, Inc. (Nasdaq - APRN), Chico’s FAS, Inc. (NYSE - CHS)
From Brodsky & Smith LLC
Via GlobeNewswire
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Via Benzinga
Vericity, POINT Biopharma Global, Oddity Tech And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Falls Over 100 Points; McCormick Sales Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.